Lee Hyoung-Song, Kim Min Jee, Ko Duck Sung, Jeon Eun Jin, Kim Jin Young, Kang Inn Soo
Laboratory of Reproductive Biology and Infertility, Cheil General Hospital and Women's Healthcare Center, Kwandong University College of Medicine, Seoul, Korea.
Department of Obstetrics and Gynecology, Cheil General Hospital and Women's Healthcare Center, Kwandong University College of Medicine, Seoul, Korea.
Clin Exp Reprod Med. 2013 Dec;40(4):163-8. doi: 10.5653/cerm.2013.40.4.163. Epub 2013 Dec 31.
Preimplantation genetic diagnosis (PGD) is an assisted reproductive technique for couples carrying genetic risks. Charcot-Marie-Tooth (CMT) disease is the most common hereditary neuropathy, with a prevalence rate of 1/2,500. In this study, we report on our experience with PGD cycles performed for CMT types 1A and 2F.
Before clinical PGD, we assessed the amplification rate and allele drop-out (ADO) rate of multiplex fluorescent polymerase chain reaction (PCR) followed by fragment analysis or sequencing using single lymphocytes. We performed six cycles of PGD for CMT1A and one cycle for CMT2F.
Two duplex and two triplex protocols were developed according to the available markers for each CMT1A couple. Depending on the PCR protocols, the amplification rates and ADO rates ranged from 90.0% to 98.3% and 0.0% to 11.1%, respectively. For CMT2F, the amplification rates and ADO rates were 93.3% and 4.8%, respectively. In case of CMT1A, 60 out of 63 embryos (95.2%) were diagnosed and 13 out of 21 unaffected embryos were transferred in five cycles. Two pregnancies were achieved and three babies were delivered without any complications. In the case of CMT2F, a total of eight embryos were analyzed and diagnosed. Seven embryos were diagnosed as unaffected and four embryos were transferred, resulting in a twin pregnancy. Two healthy babies were delivered.
This is the first report of successful pregnancy and delivery after specific PGD for CMT disease in Korea. Our PGD procedure could provide healthy babies to couples with a high risk of transmitting genetic diseases.
胚胎植入前遗传学诊断(PGD)是一项针对有遗传风险夫妇的辅助生殖技术。夏科-马里-图斯(CMT)病是最常见的遗传性神经病变,患病率为1/2500。在本研究中,我们报告了针对1A型和2F型CMT进行PGD周期的经验。
在临床PGD之前,我们使用单个淋巴细胞评估多重荧光聚合酶链反应(PCR)后的扩增率和等位基因脱扣(ADO)率,随后进行片段分析或测序。我们对1A型CMT进行了6个周期的PGD,对2F型CMT进行了1个周期的PGD。
根据每对1A型CMT夫妇可用的标记物,开发了两种双重和两种三重方案。根据PCR方案,扩增率和ADO率分别为90.0%至98.3%和0.0%至11.1%。对于2F型CMT,扩增率和ADO率分别为93.3%和4.8%。在1A型CMT的情况下,63个胚胎中有60个(95.2%)被诊断出来,在5个周期中,21个未受影响的胚胎中有13个被移植。实现了2次妊娠,分娩了3名婴儿,无任何并发症。在2F型CMT的情况下,共分析和诊断了8个胚胎。7个胚胎被诊断为未受影响,4个胚胎被移植,导致双胎妊娠。分娩了2名健康婴儿。
这是韩国首例针对CMT病进行特定PGD后成功妊娠和分娩的报告。我们的PGD程序可以为有高遗传疾病传播风险夫妇提供健康婴儿。